Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Oral vitamin K anticoagulation (warfarin, Coumadin, coumarin) has long been used for long-
term treatment and prophylaxis in a variety of clinical settings. Given the unpredictable …

Objective Apixaban is a substrate of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein.
The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the …

Objectives During anticoagulant therapy, major bleeding is one of the most severe adverse
effects. This study aimed to evaluate the relationships between ABCB1, ABCG2, and …

The use of direct oral anticoagulants (DOACs) is increasing because of their superior
efficacy and safety compared with vitamin K antagonists. Pharmacokinetic drug interactions …

This analysis describes the population pharmacokinetics (PPK) of apixaban in nonvalvular
atrial fibrillation (NVAF) subjects, and quantifies the impact of intrinsic and extrinsic factors …

The population pharmacokinetics (PK) of rivaroxaban have been evaluated in several
population‐specific models. We developed an integrated population PK model using pooled …

Apixaban is approved for treatment of venous thromboembolism (VTE) and prevention of
recurrence. Population pharmacokinetics, pharmacokinetics–pharmacodynamics (anti‐FXa …

The non-vitamin K antagonist oral anticoagulants (NOACs) exert their anticoagulant effect
closely related to their plasma concentrations. Since their distribution volume is related to …

The introduction of oral direct anti-Xa anticoagulants apixaban and rivaroxaban has
significantly impacted the treatment and prevention of thromboembolic disease. Clinical …